Table 6.
Multivariate analysis of OS on pretreatment quality of life of QLQ-C30 among 501 patients with nasopharyngeal carcinoma
| HR | 95%CI | P | |
|---|---|---|---|
| Age | 1.329 | 0.516–3.427 | 0.556 |
| Gender | 0.493 | 0.136–1.795 | 0.284 |
| Marriage | 1.524 | 0.226–10.298 | 0.665 |
| Education | 1.145 | 0.763–1.720 | 0.513 |
| Smoking history | 1.246 | 0.483–3.216 | 0.650 |
| Alcohol history | 0.268 | 0.034–2.125 | 0.213 |
| T stage | 2.353 | 0.539–10.275 | 0.255 |
| N stage | 1.675 | 0.686–4.090 | 0.257 |
| Pre-treatment EBV DNA | 0.816 | 0.342–1.946 | 0.646 |
| Post-treatment EBV DNA | 11.202 | 1.473–85.184 | 0.020 |
| Pain | 1.028 | 0.996–1.061 | 0.091 |
| Swallowing | 1.014 | 0.978–1.050 | 0.458 |
Abbreviations: OS Overall sruvival, HR Harsard ratio